Abstract
Since the global withdrawal of Sabin 2 oral poliovirus vaccine (OPV) from routine immunization, the Global Polio Eradication Initiative (GPEI) has reported multiple circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. cVDPV2 outbreaks are controlled using mass vaccination with Sabin 2 OPV, which carries a small, but serious risk of seeding future cVDPV2 outbreaks in settings of low population immunity. Accurate forecasting models are essential to quantify transmission and reversion risk to optimize effectiveness of mass OPV2 campaigns and minimize cVDPV2 emergence risk. Here, we developed an agent-based model of Sabin 2 vaccine transmission to simulate and to assess the role of household community structure on transmission during a clinical trial designed to monitor community transmission following a mass OPV campaign in Matlab, Bangladesh. Our results emphasize the role of household and community membership and shows that vaccine virus transmission occurs primarily between local community members. When constructing disease forecasting models, ignoring community structure and asserting mass action systematically overestimates emergence probability, duration, and epidemic size due to mechanistic differences in how transmissions are distributed. Model forecasting of vaccine transmission and cVDPV2 emergence risk must incorporate existing knowledge regarding community and social contact structure to provide accurate assessments of transmission risk and ensure the efficacy of future cVDPV2 containment and prevention strategies.
Significance Statement The emergence of multiple Sabin 2 circulating, vaccine-derived poliovirus (cVDPV2) outbreaks since the withdrawal of Sabin 2 oral poliovirus from routine immunization scales threatens to undermine global eradication efforts. Disease forecasting models are invaluable tools for evaluating transmission and outbreak risk but it is unclear how relevant social behavior and household community model is for cVDPV2 outbreak forecasting. Understanding the interaction between social contact structure and disease transmission is critical for accurate risk assessment but is frequently ignored in outbreak forecast models. Our study utilizes data from a cluster-randomized vaccine trial designed to trace Sabin 2 vaccine virus transmission to assess whether model forecasts that ignore social community structure are appropriate for informing public policy.
Competing Interest Statement
Grant funding was obtained from the Bill & Melinda Gates Foundation. ASB, is employed by the funder and contributed to the designing of the original clinical trial, model interpretation and writing of the report. All other authors declare no competing interests. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Funding Statement
This study was funded by the Bill & Melinda Gates Foundation (OPP112545 to Petri and Taniuchi, OPP1198444 to Taniuchi).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This original clinical trial (ClinicalTrials.gov, number NCT02477046) was done according to the guidelines of the Declaration of Helsinki. The protocol was approved by the Research Review Committee (RRC) and Ethical Review Committee (ERC) of the icddr,b and the Institutional Review Board of the University of Virginia.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data requests regarding the clinical trial should be made to the Dr. Mami Taniuchi. This trial is registered at ClinicalTrials.gov, number NCT02477046. The model and code used in this study will be available on Github (https://github.com/InstituteforDiseaseModeling/MultiscaleModeling.git) at the time of publication.
